Your experts in CHO and HEK293.
FEATURED
Announcement of Accepted Publication
We are happy to announce a second generation, improved host cell line for AAV production and for stable gene expression in HEK293 cells.
A HEKExpress® clonally derived T-antigen-negative HEK cell line called HEKzeroT® has been generated with superior productivity and which also eliminates safety concerns when producing recombinant Adeno-Associated Viruses (rAAV) for clinical purposes. The cell line is rapidly growing in chemically defined media and is scalable for large scale production.
Stay tuned to get a copy of the official publication when it’s released by signing up for our newsletter below.
Our services
Expect great science. It’s in our DNA.
Our services in stable cell line development and recombinant protein manufacturing cover the value chain – from DNA construction and transfection to CHO and HEK process development, to large-scale protein production. Our cGMP compliant facility enables the generation of Master Cell Banks and Master Working Banks (MCB, MWB).
ExcellGene’s reliable process and exceptional CHO cell host are the result of over twenty years of innovation and fine-tuning. Here’s what you can expect.
High Titers
Up to 14 g/L, fully chemically defined process
Speedy timelines
Diverse protein formats
mAbs, bispecifics, fusion proteins, biosimilars, virus surface proteins
Robust cells for scalable processes
100 L, 500 L, 2000 L, 10’000 L
Cell line development
Early on in our development of the CHOExpress® and HEKExpress® systems, we were able to identify highly stable and robust cell lines for transfection, production and scale-up. Because of this, we can now develop cell lines in less than 5 months.
cGMP master cell banking
We provide the highest standard of quality at our Swissmedic inspected facility. Our flexible cGMP plant allows banking of cell cultures for clients that use an immortalized cell line for protein production.
Rapid protein production
Get up to 200 mg of protein in 3 weeks and up to 20 g of protein in 2 months. Our proprietary transient gene expression CHOExpress® and HEKExpress® cells have been optimized for rapid growth, efficient DNA uptake, high protein expression and high density in suspension cultures (> 30 million cells/mL).
AAV production
Tox material production
Have you been limited by not having enough materials to properly design your pre-clinical studies in animals? ExcellGene will help you plan experiments without the worry of running short of materials. We can deliver up to 500 grams of drug substance from a single batch.
Our technologies
A uniquely science-driven CDMO
Since 2001, ExcellGene has developed proprietary technologies and know-how that are key for the delivery of its clients’ projects on a timely manner and with a high degree of customization.
- CHO4Tx® transfection kit: an easy to use in-house TGE protein expression kit;
- CHOExpress® host cells: the fastest growing CHO host for biotech;
- HEKExpress® host cells – a pioneering single-cell suspension host system for TGE and VLP production.
About us
We serve biotech solutions worldwide
We’ve provided biologics and biotech solutions to hundreds of clients, including 6 of the top 10 pharmaceutical firms, biotech companies, contract research organizations and academic institutions.
- Biotech 47%
- Big pharmaceutical 25%
- Academic 11%
- Other 18%
Recents posts
A superior HEK cell line for AAV production
A superior HEK cell line for AAV productionWriter's Insight Derived from ExcellGene's HEKExpress® cells, a widely used cell system known for its transient and stable protein expression, a new host system with superior performance has been developed. This innovative...
EXCELLGENE, Switzerland, and LOTTE BIOLOGICS, South Korea, Announce a Collaboration for Cell Line Development and Manufacturing of Biologics.
EXCELLGENE, Switzerland, and LOTTE BIOLOGICS, South Korea, Announce a Collaboration for Cell Line Development and Manufacturing of Biologics.PRESS RELEASETues 4th April, 2023LOTTE BIOLOGICS and EXCELLGENE today announced the signing of a Memorandum of Understanding to...
Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
Innovation in Vaccine Manufacturing
Download the PDF Innovation in Vaccine Manufacturing